



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 35/76, 39/00, 39/12 A61K 39/21, 45/05	A1	(11) International Publication Number: WO 89/ 04663 (43) International Publication Date: 1 June 1989 (01.06.89)
(21) International Application Number: PCT/US88/04128 (22) International Filing Date: 18 November 1988 (18.11.88) (31) Priority Application Number: 122,027 (32) Priority Date: 18 November 1987 (18.11.87) (33) Priority Country: US (71) Applicant: STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION on behalf of OREGON HEALTH SCIENCES UNIVERSITY [US/US]; P.O. Box 3175, Eugene, OR 97403 (US). (72) Inventor: NEUWELT, Edward, A. ; 4246 SW McDonnell Terrace, Portland, OR 97201 (US).		(74) Agents: POLLEY, Richard, J. et al.; Klarquist, Sparkman, Campbell, Leigh & Whinston, One World Trade Center, Suite 1600, 121 S.W. Salmon Street, Portland, OR 97204 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH, CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR THE DELIVERY OF GENETIC MATERIAL ACROSS THE BLOOD BRAIN BARRIER (57) Abstract <p>A method for treating genetic and acquired brain disorders is disclosed in which genetic material is introduced into the blood stream for delivery to the brain. Prior to delivery, the interendothelial structure of the BBB is chemically altered to permit passage of the genetic material therethrough. This is accomplished through osmotic disruption of the BBB by administration of suitable chemical agents. Prior to administration, the genetic material can be inserted within the genome of a viral vector preferably incapable of replication <i>in vivo</i>. After crossing the blood brain barrier, the vector containing the genetic material enters the brain tissues where it delivers in a site-specific manner the genetic material in order to control adverse effects of the disease caused by defective genes. After delivery of the genetic material, the replication-defective character of the viral vector prevents its reproduction.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-/-

METHOD FOR THE DELIVERY OF GENETIC MATERIAL
ACROSS THE BLOOD BRAIN BARRIER

This invention was made with Government support under a grant from the Veterans Administration. The Government has certain rights in this invention.

5

BACKGROUND OF THE INVENTION

The present invention generally relates to the treatment of genetic and metabolic brain disorders, and more particularly to a method for treating genetic and neurodegenerative diseases involving the delivery of corrective genetic materials into the brain.

A large variety of genetic brain disorders, such as Tay-Sach's disease, Alzheimer's disease and Parkinsonism, have been detected, researched and classified. As early as 1902, Sir Archibald Garrod first recognized genetic enzyme deficiency diseases and classified them as "inborn errors of metabolism." Since that time, extensive research has been conducted on the treatment of genetic brain disorders.

For example, in the last twenty-five years, over 360 specific catabolic enzyme deficiency diseases have been characterized. Recent biochemical and genetic research has identified the causes of more than 120 of these diseases, as discussed in McKusick, V. A., Mendelian Inheritance in Man, John Hopkins University Press, Baltimore, Maryland, 1978.

35

-2-

Most diseases involving genetic enzyme deficiencies are characterized by motor and mental deterioration leading to early death. A major group of neurodegenerative genetic enzyme disorders involves diseases classified as "lysosomal storage diseases". Lysosomes are the principal site of intracellular digestion. They consist of membrane-encapsulated vesicles containing more than forty acid hydrolases capable of degrading most biologically important macromolecules, as discussed in Dean, R.T. et al, "Lysosomes", Essays In Biochemistry 12:1 - 40, 1976. Lysosomal storage diseases result from either the deficiency or nonfunctionality of one or more of the lysosomal hydrolases. These disorders are further characterized by the accumulation of the glycosphingolipid or glycosaminoglycan substrate of the deficient enzyme in the lysosome.

A wide variety of neurodegenerative lysosomal storage diseases exist, some of which are listed below in Table I.

TABLE I

<u>Disease</u>	<u>Enzyme Deficiency</u>
25 SPHINGOLIPIDOSES:	
GM ₁ gangliosidosis	β -Galactosidase
GM ₂ gangliosidosis:	
Classical Tay-Sachs	Hexosaminidase A
Sandhoff's Variant	Hexosaminidase A&B
30 AB Variant	GM activator
Metachromatic Leukodystrophy	Arylsulfatase A
Krabbe Disease	Galactocerebrosidase
Fabry Disease	α -galactosidase A
Gaucher Disease	β -glucosidase
35 Niemann-Pick	Sphingomyelinase

-3-

MUCOPOLYSACCHARIDOSES:

	Hurler and/or Scheie	α -Iduronidase
	Hunter Syndrome	Iduronate Sulfatase
	Sanfilippo Disease:	
5	Type A	Heparin-N-sulfamidase
	Type B	α -N-Acetylgluco- saminidase
	Type C	Heparin-N-Acetyl- transferase
10	Type D	α -N-glucosamine- 6-sulfatase
	Marguio Disease	
	Type A	Galactosamine- α - sulfate sulfatase
15	Type B	β -Galactosidase
	Maroteaux-Lamy	Arylsulfatase B
	Sly Disease	β -Glucuronidase
	DiFerrante	Glucosamine-6-sulfate -sulfatase
20		

Most of the diseases listed in Table I actually involve several genotypic and phenotypic variations which have been grouped together on the basis of the defective enzyme.

25 Research involving genetic enzyme deficiencies has had a significant impact on reproductive counseling. It is now possible in many cases to reliably detect carrier heterozygotes as well as prenatally diagnose defective fetuses.

30 Unfortunately, prenatal diagnosis is complicated by the fact that each disease is rare. Thus, at-risk carrier couples are often not identified until after an affected child is diagnosed.

35

-4-

In addition, some enzyme deficiency diseases may affect certain subpopulation groups more than others. For example, it is now possible to detect at an early stage the existence of
5 Tay-Sachs disease in individuals of Ashkenazi Jewish ancestry. However, even when effective screening programs for such diseases exist, they may not be used because of moral or religious convictions. Likewise, elective abortion is not always an
10 acceptable consideration for similar reasons.

While carrier detection and prenatal diagnosis has had some impact in minimizing the number of individuals afflicted with genetic enzyme deficiency diseases, many problems still exist. A
15 need therefore exists for an effective therapeutic program to control genetic enzyme deficiencies in patients having these diseases.

A variety of methods have been used to treat patients having genetic enzyme deficiencies, including lysosomal storage diseases. Current,
20 research indicates that the etiology of these diseases at least partially results from a decreased concentration of the deficient enzyme product, as discussed in Barranger, J.A., "Feasibility of Enzyme
25 Replacement in Brain: An Overview.", Advances in the Treatment of Inborn Errors of Metabolism, John Wiley, London, 1982. Therefore, a possible therapeutic strategy would be to provide enough of the deficient enzyme product to restore its
30 concentration to normal levels.

Another possible theory explaining the pathogenesis of lysosomal storage diseases involves accumulation of the substrate of the affected
enzyme. Thus, alternative therapeutic strategies
35 might include methods of reducing the concentration

-5-

of excess enzyme substrate. Methods of accomplishing this involve dietary therapy and chelation of stored metabolites, as well as other methods which decrease the synthesis of the substrate by metabolic inhibition. While these methods have met with success in treating certain diseases (e.g., phenylketonuria), a large number of diseases remain which are not amenable to this type of treatment. In certain diseases, the excess substrate is an essential metabolite that is not readily regulated, and is synthesized throughout the body.

The treatment of genetic lysosomal storage diseases must therefore be approached from a dual standpoint: (1) the control of excess substrate accumulation; and (2) increasing the level of deficient enzymes. To accomplish these goals, a third category of therapeutic treatment may be possible which is called "enzyme replacement therapy." Using this method of treatment, properly administered exogenous enzymes gain access to substrate-engorged lysosomes via fusion with a primary lysosome. The administered enzyme can then restore the normal catabolic function of the affected lysosome. However, there are several problems associated with enzyme replacement therapy, described as follows:

1. Enzyme Delivery Problems -- A major problem involving the delivery of exogenous enzymes is that of the blood brain barrier (BBB). The BBB is a capillary barrier comprising a continuous layer of endothelial cells which are tightly bound. The BBB excludes molecules in the blood from entering the brain on the basis of both molecular weight and lipid solubility, as described in Neuwelt, E. A. et al, "Is There A Therapeutic Role For Blood-Brain

-6-

Barrier Disruption?", Ann. Int. Med. 93:137-139, 1980; Rapoport, S.I., Blood-Brain Barrier in Physiology and Medicine, Raven Press, N.Y. 1976. For example, the BBB normally excludes molecules
5 with a molecular weight greater than 180 daltons. Similar exclusion occurs on the basis of lipid solubility.

One method of passing agents through the BBB involves osmotic disruption of the barrier by
10 the administration of hypertonic mannitol or other agents, as described in Neuwelt, E.A., "Osmotic Blood-Brain Barrier Modification: Monoclonal Antibody, Albumin, and Methotrexate Delivery to Cerebrospinal Fluid and Brain", Neurosurgery,
15 17:419-423, 1985; Rapoport, supra. Disruption of the BBB using this method is caused by a shrinkage of the cerebrovascular endothelial cells, which increases the permeability of the interendothelial junctions.

20 However, numerous problems exist when exogenous enzymes are administered. Tests indicate that low amounts of enzymes are actually delivered, since organ-derived, purified lysosomal enzymes injected into a patient's blood stream are rapidly
25 cleared, with a half life in the range of several minutes as described in Ratazzi, N., "Enzyme Therapy in Lysosomal Storage Diseases: Current Approaches.", Human Genetics - Part B: Medical Aspects 573-587, 1982. Organ biopsies and
30 radioimmunoassay demonstrate that the exogenous enzyme is found mainly in the liver, with only minimal activity detectable in extrahepatic tissues. This rapid clearance is most likely caused by hepatic receptors which recognize terminal
35 mannosyl and N-acetyl- glucosaminy residues on the lysosomal enzymes.

-7-

Another problem involving the direct delivery of exogenous enzymes is the likelihood that a recognition marker will be required for proper enzyme uptake, as indicated in Hickman, S. et al, "A
5 Recognition Marker Required For Uptake of Lysosomal Enzyme By Cultured Fibroblasts.", Biochem. Biophys. Res. Comm. 57:55-61, 1974. Accordingly, effective enzyme replacement therapies will not only require
10 administration of a highly stable, very specific enzyme which is protected from hepatic clearance, but the enzyme must also bind to a receptor with a high affinity that will deliver the enzyme to the proper intracellular compartment.

2. Problems Involving the Availability of
15 Enzyme Supplies: -- Many of the needed enzymes required for effective enzymatic therapy are difficult and costly to obtain. Likewise, such enzymes frequently must be administered at numerous intervals, requiring substantial amounts of
20 materials to be obtained. It may also take months or even years of enzyme administration for the treatment to be effective.

3. Problems Involving Protection of the
25 Enzyme: -- In addition to protecting the administered enzymes from rapid renal clearance, the enzymes must also be protected from the patient's immune system, as described in Poznanski, M. J., "Enzyme-Protein Conjugates: New Possibilities For Enzyme Therapy", Pharmac. Ther. 21:53-76, 1983.
30 Adverse immunological responses are particularly evident when the administered enzymes are derived from fungal or bacterial sources. Also, there is the possibility of acute enzyme toxicity caused by the administration of large doses of enzymes. This
35 toxicity may be manifested in acute hyperproteïnemia.

-8-

Thus, there are numerous problems associated with the direct administration of purified exogenous enzymes in the treatment of lysosomal storage diseases. There have been human
5 trials involving this method, all of which have met with minimal success. A key problem remaining in exogenous enzyme replacement therapy is the delivery of enzymes across the blood brain barrier, as described above. In order to overcome this problem,
10 another treatment method has been tested which involves direct tissue transplantation.

The first use of organ replacement therapy in a genetic storage disease involved a spleen allograft in a patient having Gaucher's disease, as
15 described in Groth, C.G. et al "Splenic Transplantation In a Case of Gaucher's Disease", Lancet 1:1260-1264, 1971. However, no clinical improvement in the patient was noted, and death occurred several months following a severe tissue
20 incompatibility response. Other tests were conducted involving kidney grafts and liver transplantations, all of which were minimally successful.

Thus, organ and tissue transplantation has
25 not been effective in treating lysosomal storage diseases that affect the CNS. Transplanted organs do not appear to synthesize and/or release sufficient quantities of enzymes in order to control the disease. Even if the transplantation did result
30 in circulation of sufficient amounts of enzymes as has been the case with bone marrow transplants in some of the mucopolysaccharidoses, there is still the problem of delivery across the BBB.

A need therefore exists for a treatment
35 therapy effective in controlling the effects of genetic enzyme deficiency diseases and other genetic and metabolic brain disorders, including

-9-

Parkinsonism and Alzheimer's disease. For example, in Parkinsonism, there is a deficiency of dopamine which may benefit from increased levels of the enzyme tyrosine hydroxylase. There is also some evidence that in Alzheimers's disease there is a deficiency of choline acetyl transferase (CAT). Finally, there is a need for a treatment therapy which minimizes the problems associated with traditional treatment methods. These problems include transport across the BBB, adverse immunological responses, rapid renal clearance and other physiological difficulties.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide an effective method for treating genetic and acquired metabolic brain disorders.

It is another object of the invention to provide a method for treating genetic and acquired metabolic brain disorders which avoids adverse immunological side effects.

It is a further object of the invention to provide a method for treating genetic and acquired metabolic brain disorders which avoids renal clearance problems associated with the direct infusion of purified exogenous enzymes.

It is a further object of the invention to provide a method for treating genetic and acquired metabolic brain disorders which avoids problems inherent in methods involving tissue transplantation.

It is a further object of the invention to provide a method for treating genetic and acquired metabolic brain disorders which uses readily available, relatively inexpensive materials.

It is a still further object of the invention to provide a method for treating genetic and acquired metabolic brain disorders which

-10-

involves providing corrective genetic material to the brain in order to effectively treat the disorder on a molecular level.

5 To accomplish these objectives, a method for treating genetic and acquired metabolic brain disorders (e.g. neurodegenerative lysosomal storage diseases) is disclosed in which corrective genetic material is inserted directly into the brain. This is preferably accomplished using a specially
10 prepared viral vector containing corrective genetic material. It is desirable that the virus be incapable of replication so that delivery of the virus can occur without the formation of viral progeny. Prior to delivery of the viral vector into
15 the brain, the interendothelial structure of the BBB is chemically altered to increase its permeability. This is preferably accomplished through osmotic disruption of the BBB by the administration of suitable chemical agents. The viral vector is then
20 permitted to enter the brain tissues where it delivers in a site-specific manner the corrective genetic material in order to control adverse effects of the disease caused by defective genes.

25 Using this procedure, the pathogenesis of neurodegenerative enzyme deficiency diseases and other brain disorders would be eliminated. Likewise, excessive renal clearance, adverse immunological responses, and other problems associated with tissue transplantation or direct introduction of exogenous
30 enzymes are avoided.

These and other objects, features, and advantages of the invention will be described hereinafter in the following detailed description of a preferred embodiment.

35

DETAILED DESCRIPTION

-11-

The present invention involves a treatment method in which the blood brain barrier is chemically altered to allow the passage of corrective genetic material. Preferably, the
5 corrective genetic material will be carried by a vector such as a virus. This strategy completely bypasses many of the problems inherent in transplantation and enzyme replacement techniques. It instead focuses on the cause of the problem,
10 namely, a mutant gene.

A particularly useful method involves the packaging of corrective genetic material in a viral vector as illustrated by the following discussion.

15 Preparation of a Retrovirus Vector

In gene replacement therapy, the replaced gene must not only be delivered to the proper tissue, but must achieve access to the proper
20 intracellular regions. This can be accomplished by using a virus or retrovirus (hereinafter referred to as a "viral vector").

The genome of a retrovirus includes the gag, pol and env genes. Gag codes for viral capsid
25 proteins, env for proteins that will be incorporated into the outer membrane, and pol for the reverse transcriptase and integrase enzymes.

Infection of a host cell by a retrovirus results in the release of two copies of the single
30 stranded retroviral RNA genome, and the enzymes reverse transcriptase and integrase contained within the virion core. Reverse transcriptase transcribes the RNA genome into an RNA-DNA
heteroduplex and then into a DNA duplex forming two
35 complete long-terminal repeats (LTR's) in the process. A covalently closed circle is then formed

-12-

by non-homologous recombination between the distal regions of the two LTRs. A site is recognized by the retroviral enzyme integrase which catalyzes insertion of the viral genome into the host cell genome. This insertion is site specific with respect to the retrovirus, but random with respect to the host.

Once the viral genome is integrated into the host cell genome, transcription is initiated and viral genes are under the influence of a retroviral promoter. The retroviral genome contains two sites which are referred to as the splice donor (S.D.) and splice acceptor (S.A.) sites. During transcription, the S.D. site is capable of directing the gag, pol genetic regions to be spliced out. This results in transcription of the subgenomic RNA containing the env gene. However, the S.D. site is only about 50% effective. As a result, only half of the time RNA polymerase reads through the S.D. site and the full length genomic RNA containing the gag and pol gene region is transcribed. Translation of these transcripts forms the essential retroviral proteins which enable formation of the viral particle. It is important to note that only the genomic RNA containing the encapsidation site ψ is incorporated into the virion.

When using a retroviral vector for the transfer of genes into cells, one of the concerns that must be dealt with is the undesirable effect of replicating viruses. One means of eliminating this problem has been the construction of trans-defective, cis-active retroviral vectors. The cis portion of the retroviral genome includes the long terminal repeat (LTR) sequences, the primer binding site, the polypurine tract, and the ψ sequences necessary for viral RNA packaging

-13-

(encapsidation). The other regions of the retroviral genome necessary for replication are referred to as trans portions. These regions encode the viral proteins gag, pol and env, along with the control elements and splice donator/acceptor sites necessary to express them. Thus, a cis-active, trans-defective retrovirus is one in which a trans region gene such as gag, pol or env has been partially or completely deleted or replaced with another gene. Such a retrovirus is able to undergo reverse transcription and integration as a DNA provirus. The integrated provirus can be transcribed by the RNA polymerase of the host cell to yield full length (and subgenomic) polyadenylated viral RNAs capable of being incorporated into virions that bud from the cell. This trans-defective retrovirus, however, does not encode all of the gag, pol, and env gene products essential for its own propagation and is therefore replication defective.

As described in Wigler, M., et al, "Transformation Of Mammalian Cells With an Amplifiable Dominant Acting Gene", Proc. Natl. Acad. Sci. 77:3567-3571, 1980, trans-defective retroviruses have been utilized as vectors for the transfer of cloned selectable and non-selectable genes. In general, the gene of interest is inserted into the retroviral sequence coding for the genomic RNA in the place of the gag-pol trans gene, and a selectable marker gene is inserted into the sequence encoding the subgenomic mRNA in place of the env trans gene. A commonly used marker is the neo gene, which confers G418 resistance in eukaryotes and kanamycin resistance in bacteria.

Transfection of an appropriate cell with a vector retrovirus will result in expression of the

-14-

gene and selectable marker genes under the control of the retroviral transcriptional regulators, but will not result in the release of retroviral progeny because of the lack of essential gene products.

5 One consequence of the inability of the vector retrovirus to propagate itself is that a helper virus is required to generate the vector retrovirus. When an appropriate cell is infected with the trans-defective vector retrovirus, it is
10 superinfected with a trans-active helper virus which provides deficient viral products and allows packaging of the vector RNA. The need for a helper virus has been overcome by the construction of
15 cis-defective retroviruses which are packaging mutants. The region of this mutation is distal of the splice donor site and upstream of the transcriptional start of the gag, pol regions. The mutation region contains the site which is essential for the encapsidation of the viral genome. Thus, a
20 packaging cell line contains a ψ deficient retrovirus genome but does contain the helper virus gag, pol and env gene products which can be used to package retroviral RNAs into virions.

 Retroviral vectors are only suitable for
25 the delivery of cDNA clones. Such clones are mRNA complements which do not contain the introns of the full-length genomic genes. This limitation is a result of size constraints (approximately 8 kilobase pairs) and the fact that genomic clones inserted
30 into retroviral vectors will be spliced down to the mRNA complement during the first retroviral generation.

 cDNA clones can be created from purified
35 mRNA in a variety of ways such as by the addition of a polythymidine primer to the purified mRNA template, as outlined in Horwich, A.L. et al,

-15-

"Strategies For the Molecular Cloning Of Low Abundance Messenger RNA's", Molecular Basis Of Lysosomal Storage Disorders, Academic Press, 1984.

DNA polymerase I is then used to synthesize the
5 negative strand of DNA. Following completion of this reaction, the original RNA component of the previously formed heteroduplex can be preferentially degraded by the addition of alkali. A second primer is not required to continue the reaction because the
10 3' end of the newly synthesized DNA strand is able to bend back on itself to form a "hairpin loop" primer. Reverse transcriptase also has a DNA polymerase function and is able to synthesize the second DNA strand using the first strand as a
15 template. The reaction is completed by removing the hairpin loop through the addition of S1 nuclease which specifically cleaves single stranded nucleic acids. It should be noted that cDNA clones formed in this manner are always deficient of a short
20 stretch complementary to the 5' region of the mRNA because of the removal of the hairpin loop region. Another method for generating full length duplex cDNA involves the enzyme RNase H. This enzyme nicks the RNA strand of an RNA-DNA
25 heteroduplex. In this procedure the first strand cDNA synthesis is carried out as previously described, then the RNA is removed by treating the heteroduplex with RNase H and subsequently using DNA polymerase I for second strand synthesis.

30 Once a duplex cDNA of interest has been obtained, the next step is to generate a large number of copies. This is accomplished by inserting the clone either into a plasmid vector containing a selectable marker and transforming a bacterial cell
35 line or by inserting the clone into a bacteriophage and transfecting the cell line. The most commonly

-16-

used bacteriophages are the λ gt10 and λ gt11
vectors. Libraries constructed with these vectors
have the advantages of being more easily screened as
well as the fact that transfections are accomplished
5 at a higher rate of efficiency than trans-
formations.

The first step in the plasmid procedure
involves cleavage of the vector with a Type II
restriction endonuclease. EcoRI is one example of
10 this type of restriction endonuclease. EcoRI
recognizes a specific six base pair sequence of DNA
and catalyzes a specific cleavage of the DNA within
the recognition sequence. This procedure creates
four long base "sticky ends". Because EcoRI always
15 creates the same ends and complementary DNA is
capable of annealing, one method of inserting a
clone into vector DNA is simply to cleave both the
vector and the clone with the same restriction
endonuclease and then allow the clone and vector to
20 anneal on the basis of the complementary nature of
the "sticky ends".

An alternative procedure to construct a
plasmid vector is entitled the "complementary
tailing" method. In this method, the vector is
25 opened with a restriction endonuclease and
complementary nucleotide tails are added to the
vector and insert DNA in separate reaction mixtures
with dioxynucleotidyl transferase. Finally, the
insert is annealed to the vector on the basis of the
30 complementary tails, and the gaps are covalently
closed with ligase. It should be noted that both of
these methods rely on selectable markers in the
vector plasmid to isolate the vectors into which the
clone has been properly inserted as opposed to the
35 vector simply recombining with itself or other
plasmids.

-17-

A popular method of cDNA cloning is described in Okayama, H., et al, "High-Efficiency Cloning of Full-Length cDNA", Molecular and Cellular Biol 2:161-170, 1982. This method combines the synthesis of duplex cDNA using the above complementary tailing method with the actual cloning into a plasmid vector for amplification. It involves annealing mRNA to an oligo dT tail already contained in a plasmid and then reverse transcribing the cDNA directly into the vector. After closure of the plasmid with a linker that is complementary to both the vector and to a synthetic tail on the cDNA, the original mRNA can be removed with E.coli RNase A, subsequently the second strand synthesis is carried out by DNA polymerase I. The advantage of this method is that there is no loss of the insert due to removal of the hairpin loop because none is required.

Using the aforementioned techniques, a retrovirus can be prepared which includes a suitable cDNA clone for use in the treatment of genetic brain disorders or other metabolic diseases.

Once the viral vector is prepared, it must be able to pass through the BBB. To accomplish this, the vector is directly administered to the patient in conjunction with osmotic disruption of the BBB. Administration of the vector should be completed within 1-2 minutes after BBB disruption since disruption occurs for only a short period of time. Osmotic disruption of the BBB may be accomplished using hypertonic mannitol or other hypertonic solutions. Specific methods of BBB modification are discussed in Neuwelt, E.A., "Osmotic Blood-Brain Barrier Modification: Monoclonal Antibody, Albumin, and Methotrexate Delivery to Cerebrospinal Fluid and Brain", supra.

-18-

Once entry of the vector is accomplished, its corrective genetic material is incorporated in affected tissues. The genetic material is typically only incorporated in replicating cells. Replication occurs slowly in glia and little if at all in neurons. Thus, growth or maturation factors (i.e. glial maturation factor, or nerve growth factor) may also be needed for the corrective gene material to be integrated. It is likely that only glia will be infected since mature neurons do not replicate. However, lysosomal enzymes are partially released into the extra-cellular space and then taken up by other cells via the mannose 6 phosphate receptor which is present on neurons. Therefore, infected glia may supply enzyme to neurons.

Delivery Across the Blood Brain Barrier

The successful delivery of a virus across the blood brain barrier of a subject organism according to the present invention is illustrated by the following procedure for the intracarotid delivery of ^{35}S Herpes virus into the brain tissues of laboratory rats.

25

A. Methods and Materials

Adult, female, Sprague-Dawley rats were anesthetized with sodium pentobarbital (50mg/kg, intraperitoneal). A catheter filled with sodium heparin in isotonic 0.9% NaCl was tied into the right external carotid artery for retrograde infusion. Five minutes prior to BBB modification, Evans blue was administered intravenously (2%; 2ml/kg). Mannitol (25%) warmed to 37°C was then infused for 30 seconds cephalad into the right internal carotid artery through the right external

-19-

carotid artery catheter at a rate of 0.12ml/sec. As described herein, mannitol will increase the permeability of the BBB. In control animals, 0.9% NaCl solution instead of mannitol was used at an identical rate and volume.

Next, U.V. inactivated ^{35}S -Herpes virus was administered at three different dosage levels as an intracarotid bolus, over a 30 second time period one minute after mannitol/saline infusion. One hour later, a serum sample was collected and the rat perfused with 0.9% sodium chloride to clear the vascular system of radioactivity. Samples were then collected from the rat brain including the contralateral hemisphere (LH), disrupted or right hemisphere (RH), and liver (L). The samples were then weighed, solubilized, and counted in a liquid scintillation cocktail for activity. To determine the amount of activity associated with protein (virus), samples were weighed and homogenized in 0.5ml saline and an aliquot of homogenate was then added to an equal volume of 20% trichloroacetic acid. The samples were centrifuged at 1200 x g for 30 minutes and the resultant fractions counted in the cocktail for activity.

B. Results and Conclusions

The experimental results for three different dosages of ^{35}S -Herpes virus are described below in Tables II, III and IV.

TABLE II

DOSE: 1.0×10^6 cpm or 4.3×10^7 pfu

-20-

MANNITOL

	<u>LH</u>	<u>RH</u>	<u>LIVER</u>	<u>SERUM</u>
5	2,253	10,093	21,815	4,125
	1,514	7,803	29,370	5,745
	804	6,730	25,692	5,745
	915	8,855	26,623	5,775
	1,589	12,627	30,749	4,890
	1,317	10,199	35,960	5,170
	<u>1,399</u>	<u>9,243</u>	<u>28,368</u>	<u>5,238</u>
10	<u>% DEL</u>	<u>TCA-RH</u>	<u>TCA-Liver</u>	<u>CLEAR</u>
	1.0	- - -	- - - - -	81
	0.8	- - -	- - - - -	88
	0.7	84	82	89
	0.9	92	86	87
	1.3	88	83	87
	1.0	91	81	90
15	<u>0.95</u>	<u>89</u>	<u>83</u>	<u>87</u>

NORMAL SALINE

	<u>LH</u>	<u>RH</u>	<u>LIVER</u>	<u>SERUM</u>
20	1,301	4,110	36,544	6,160
	1,711	3,980	56,984	3,445
	<u>1,506</u>	<u>3,980</u>	<u>46,764</u>	<u>4,803</u>
25	<u>% DEL</u>	<u>TCA-RH</u>	<u>TCA-Liver</u>	<u>CLEAR</u>
	0.40	63	78	56
	0.38	85	80	70
	<u>0.39</u>	<u>74</u>	<u>79</u>	<u>63</u>

LEGEND:

30	LH:	Nondisrupted or left hemisphere (cpm/gm)
	RH:	Disrupted or right hemisphere (cpm/gm)
	Liver:	Expressed in cpm/gm
	Serum:	Expressed in cpm/ml serum

-21-

% DEL: Per cent delivered dose per gram of brain in disrupted hemisphere

TCA-RH: Per cent precipitable counts using trichloroacetic acid in disrupted brain

TCA-LIVER: Per cent precipitable counts using trichloroacetic acid in liver

5 CLEAR: Per cent clearance of activity from serum
Post-perfusion x 100
Pre-perfusion

Mean value of columns are underlined

TABLE III

10

DOSE: 2.0 x 10⁶cpm or 1.09 x 10⁸pfu

MANNITOL

	<u>LH</u>	<u>RH</u>	<u>LIVER</u>	<u>SERUM</u>
15	2,297	31,534	71,331	10,590
	2,406	26,838	77,880	11,410
	<u>2,352</u>	<u>29,186</u>	<u>74,606</u>	<u>11,000</u>
	<u>% DEL</u>	<u>TCA-RH</u>	<u>TCA-Liver</u>	<u>CLEAR</u>
	1.6	91	81	93
20	1.3	91	80	94
	<u>1.45</u>	<u>91</u>	<u>81</u>	<u>94</u>

NORMAL SALINE

	<u>LH</u>	<u>RH</u>	<u>LIVER</u>	<u>SERUM</u>
25	2,555	7,567	54,043	8,365
	525	5,126	62,801	11,350
	<u>1,540</u>	<u>6,347</u>	<u>58,422</u>	<u>9,858</u>
	<u>% DEL</u>	<u>TCA-RH</u>	<u>TCA-Liver</u>	<u>CLEAR</u>
30	0.38	78	77	81
	0.26	83	80	90
	<u>0.32</u>	<u>81</u>	<u>79</u>	<u>86</u>

(Legend same as Table II)

35

TABLE IV

DOSE: 3.0 x 10⁶cpm or 1.68 x 10⁸pfu

-22-

MANNITOL

	<u>LH</u>	<u>RH</u>	<u>LIVER</u>	<u>SERUM</u>
	0	44,490	101,174	15,335
	3,626	53,694	102,269	19,260
5	<u>1,836</u>	<u>49,092</u>	<u>101,722</u>	<u>17,298</u>
	<u>%DEL</u>	<u>TCA-RH</u>	<u>TCA-Liver</u>	<u>CLEAR</u>
	1.5	87	81	86
	1.8	92	77	92
10	<u>1.65</u>	<u>90</u>	<u>79</u>	<u>89</u>

(Legend same as Table II)

15 The animals undergoing intracarotid (IC)
 saline and subsequent IC virus at dosages of 1.0 and
 2.0 x 10⁶cpm had ipsilateral hemisphere
 concentrations which corresponded to 0.39% and 0.32%
 of the delivered dose. Contralateral hemisphere
 values were 0.15% and 0.08% of the delivered doses
 20 respectively. This suggests about a three-fold
 increase in non-specific adherence of virus to brain
 vasculature due to intracarotid administration.
 Clearance of radioactivity from serum averaged
 approximately 85% in all groups suggesting modest
 25 contamination in samples due to blood. Samples were
 not corrected for residual activity as determined by
 clearance values.

In barrier modified animals, a definite
 increase in viral concentration was evident in the
 30 ipsilateral hemisphere. At a dosage of 1.0 x
 10⁶cpm there was a 2.32 fold increase in
 disrupted brain when comparing mannitol with normal
 saline concentrations. In animals given 2.0 x
 10⁶cpm, the corresponding increase was 4.6 fold.
 35 In addition, the per cent delivered dose per gram of
 tissue in disrupted brain was 0.95%, 1.45%, and

-23-

1.65% for 1, 2, and 3 x 10⁶cpm of virus. When the values were corrected for non-specific binding as determined from the normal saline values, the delivered doses were 0.56%, and 1.13% for 1 and 2 x 10⁶cpm dosages (saline values for 3 x 10⁶cpm were not available). This again reflects an increase in viral delivery to the brain after barrier modification. Precipitation of radioactivity from disrupted brain averaged 90% in the three dosage groups, suggesting that the radioactivity remains associated with the protein (virus).

The above experiments show that the protein components of herpes virus are delivered across the BBB but do not prove delivery of assembled virus. To show the penetration of assembled virus through the BBB, the following electron microscopy (EM) studies were done.

A. In Vitro Extraction of ³⁵S-labeled Herpes Virus From Brain In Preparation for Electron Microscopy Studies

Normal rat brain was homogenized in saline at a w:v ratio of 1:5 and the homogenate was spiked with 1.0 x 10⁵cpm of ³⁵S herpes virus (UV inactivated). The sample was incubated at 37°C for 20 minutes to allow for any nonspecific binding of virus to brain protein. The sample was centrifuged for 20 minutes at 600 x g to pellet out large insoluble particulate matter and this fraction was counted for activity. It contained 60% of administered dose. The supernatant was divided into three fractions (400, 400, and 600μl) to which 100μl of antiherpes virus antibody was added. The mixtures were allowed to incubate for 20 minutes

-24-

at 37°C to allow for antibody binding. Then 100µl of protein A sepharose (specific for IgG complexes) was added to each sample and incubated for 18 hours at 4°C. The samples were
5 centrifuged at 1200 x g for 20 minutes to pellet out protein A sepharose and the resultant fractions counted.

Result: The supernatants contained 61%, 63%, and 65% (mean 63%) and the pellets 39%, 37%,
10 and 35% (mean 37%). This suggests that under these experimental conditions it is possible to extract herpes virus from a spiked brain homogenate using protein A bound to sepharose beads.

15 B. In vivo Extraction of Herpes Virus from Brain
For Electron Microscopy

The rat blood brain barrier was modified and the animal given intracarotid non-radioactive herpes virus (5×10^{10} pfu) using the identical
20 conditions as described in the ^{35}S delivery study protocol. The virus was UV inactivated. At sacrifice, the brain was removed and the disrupted and nondisrupted hemispheres collected.

The in vitro test conditions as described
25 above were carried out on a control homogenate spiked with 1×10^9 pfu, disrupted hemisphere and non-disrupted hemisphere from the experimental animal. As an additional control, aliquots of virus spiked brain and disrupted brain were incubated with
30 sepharose not bound to protein-A at the appropriate time point.

Results: There was no binding of virus to plain sepharose beads as shown by electron
microscopy. Electron micrographs showing viral
35 particles were only seen in disrupted brain using protein-A sepharose and in virus spiked brain using protein-A sepharose.

-25-

The foregoing studies therefore strongly suggest delivery of intact virus across the BBB.

Having accomplished BBB transport of an intact virus as described above, the foregoing
5 procedure may be used to transport any suitably prepared virus, retrovirus or similarly sized particle across the BBB. Retrovirus preparation may be accomplished as described above and in Mann, R. et al, "Construction of a Retrovirus Packaging
10 Mutant and Its Use to Produce Helper-Free Defective Retrovirus", Cell, 33: 153-159, 1983; and Sorge, J. et al, "Amphotropic Retrovirus Vector System For Human Cell Gene Transfer", Molecular and Cellular Biology, 4:1730-1737, 1984. Furthermore, it has
15 been proven that retroviruses carrying selected genetic material will transfect living tissues in vitro. Williams, D.A., et al, "Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse", Nature, 310:476-480, 1984.

20 Thus, the present invention represents an important advance in the treatment of genetic and/or acquired metabolic brain disorders including, but not limited to, Tay-Sach's disease, Alzheimer's disease, and Parkinson's disease. It avoids
25 problems associated with prior treatment methods, including the direct infusion of exogenous enzymes and direct tissue transplantation.

Having herein described a preferred embodiment of the present invention, it is
30 anticipated that suitable modifications may be made by those skilled in the art within the scope of the invention. For example, genetic material could be transported across the BBB apart from a vector or as a part of an assembled group of molecules that
35 contains the genetic material. The foregoing examples indicate that such groups of molecules, if

-26-

viral sized (30-300nm), should be transportable across the BBB by the same mechanism as viruses. Thus, the invention shall only be construed in accordance with the following claims.

5

10

15

20

25

30

35

-27-

WHAT IS CLAIMED IS:

1. A method for the delivery of genetic material into the cellular tissues of the brain of a human subject or other warm blooded animal subject, the method comprising the steps of:
 - chemically disrupting the blood brain barrier of the subject so as to increase the permeability thereof;
 - administering said genetic material to the bloodstream of said subject, said genetic material crossing the blood brain barrier because of its increased permeability; and
 - incorporating at least a portion of said genetic material into cellular tissues of the brain.
2. The method of claim 1 wherein said genetic material is administered to said subject intravenously.
3. The method of claim 1 wherein said genetic material is administered to said subject intra-arterially.
4. The method of claim 1 wherein said chemical disruption of said blood brain barrier involves osmotic blood brain barrier modification through the administration of a pharmaceutically effective, non-toxic hypertonic solution.
5. The method of claim 4 wherein said hypertonic solution comprises a material selected from the group consisting of mannitol, arabinose, and glycerol.

-28-

6. The method of claim 1 wherein said administering of said genetic material is accomplished within about 1-2 minutes after said chemical disruption of said blood brain barrier.

5

7. The method of claim 1 further comprising the step of inserting said genetic material into a viral vector prior to said administering of said genetic material to said subject.

10

8. The method of claim 7 wherein said viral vector comprises a retrovirus.

15

9. The method of claim 7 wherein said viral vector is replication-defective whereby it will not reproduce in vivo.

10. The method of claim 1 further comprising the step of administering a growth factor to the subject to assist in said incorporating of said genetic material.

20

11. A method for the delivery of genetic material into the cellular tissues of the brain of a human subject or other warm blooded animal, the method comprising the steps of:

25

inserting said genetic material into a retrovirus, said retrovirus being replication-defective whereby it will not reproduce in vivo;

30

chemically disrupting the blood brain barrier of said subject so as to increase the permeability thereof;

35

administering said retrovirus containing

-29-

said genetic material to said subject within about 1-2 minutes after said chemical disruption of said blood brain barrier, said retrovirus crossing said blood brain barrier because of its increased permeability; and

allowing said retrovirus to deliver said genetic material into said cellular tissues of said brain.

10 12. The method of claim 11 wherein said chemical disruption of said blood brain barrier involves osmotic blood brain barrier modification through the administration of a pharmaceutically effective, non-toxic hypertonic solution.

15 13. The method of claim 12 wherein said hypertonic solution comprises a material selected from the group consisting of hypertonic solutions such as mannitol, arabinose, and glycerol.

20


25

30

35

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/04123

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ A61K 35/76, 39/00, 39/12, 39/21 45/05 US CL 514/44; 935/52, 53; 435/172, 91		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	514/44; 935/52, 53; 435/172, 91	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
CAS -Online TM , file CA, word search		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	<u>American Journal of Physiology</u> , 250: R875-883, 1986, (NEUWELT ET AL), "Osmotic blood-brain barrier opening to IgM monclonal antibody in the rat", (See entire document)	1-13
Y	<u>Molecular and Cellular Biology</u> , vol. 4, no. 9 1984, (SORGE ET AL) "Amphotropic Retrovirus Vector System for Human Cell Gene Transfer; pages 1730-1737 (See page 1730 Abstract and first text paragraph)	1-13
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
11 January 1989		21 MAR 1989
International Searching Authority		Signature of Authorized Officer
ISA/US		 David M. Brunsman